Histopathological image of the active stage of ulcerative colitis. Credit: User:KGH / commons.wikimedia.org.

AltruBio has dosed the first subject in a Phase I clinical trial of its next-generation PSGL-1 antibody agonist, ALTB-268, in healthy volunteers to treat ulcerative colitis.

The double-blind, randomised, single- and multiple- ascending dose Phase I trial will assess the tolerability, safety, pharmacokinetics/pharmacodynamics, and immunogenicity of ALTB-268, which acts as an immune checkpoint enhancer (ICE).

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

AltruBio president and CEO Judy Chou said: “We are thrilled to bring ALTB-268 into the clinic to evaluate its safety and tolerability as a first step towards providing not only a more conveniently administered but potentially more durable and effective treatment option for patients suffering from immunological diseases including ulcerative colitis.

“The Phase I study was built on the clinically validated mechanism of action and strong preclinical data, which showcased the improved potency in eliminating pathogenic chronic T cells.

“We believe ALTB-268 can realise the ‘pipeline-in-a-product’ potential for multiple autoimmune and inflammatory diseases in a patient population with high unmet medical needs.”

Interim data from the Phase I trial is expected in the first half of this year, with plans to follow with a Phase II study commencement in ulcerative colitis.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Without interfering with cell migration, ALTB-268 helps to restore the immune system to a state of balance.

ALTB-268 is a tetravalent version of ALTB-168 and is currently being evaluated in a Phase I study, prior to advancing towards clinical studies in several inflammatory and autoimmune disorders.

The unique mechanism of action of the antibody agonist is the same as first-generation ICE, ALTB-168.

Earlier, ALTB-168 obtained positive Phase IIa results in ulcerative colitis, psoriasis, psoriatic arthritis, and SR/TR-aGVHD.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact